Skip to main content
Equibles
CAMP logo

CAMP · Camp4 Therapeutics Corp

Track CAMP — free

Use CAMP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CAMP

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.46 -0.19 (-4.09%) At close · Aug 20
Market Cap
$279.88M
Shares
62.75M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.46 Open$4.57 Day$4.37–4.95 52W close$1.41–7.13 Avg vol 30d223K Short int1.5M · 2.4% float · 8.4d Short vol11% Last earningsNov 21, 2024 DataOct 2024–Aug 2026 Filing10-Q · Aug 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −0%
below
Price vs 50-day avg +9%
above
RSI (14) 53
neutral
MACD trend Positive
52-week position 53%
mid-range
Momentum
relative strength
Weak
1-month return +48%
trailing
6-month return −1%
trailing
YTD return −27%
this year
Relative strength −12%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+30% holders QoQ · +23 funds added
Insider flow Accumulating
Net +$51.2K over 90 days · 20% sells
Short interest Rising
2.36% of float · ▲ +2.8% MoM · 8.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
61 holders — near 1-yr high, broad support
Squeeze score 61
elevated · 0–100
Fundamentals
Strong
Revenue growth +437%
Y/Y
EPS growth +76%
Y/Y
Free cash flow $-29.8M
Balance sheet $109.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 124%
annualized · 1-yr
Max drawdown −58%
past year
ATR 10.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 30, 2023
Gross margin · medium- to long-term 50%
Prior guidance period ended · from the Earnings Call filed Mar 31, 2024
Revenue · Q2 FY '24 $67M – $73M
Adjusted EBITDA · Q2 FY '24 $5M – $9M
Guided vs delivered · last 1 settled
Revenues first quarter of FY '24
guided $72M – $78M
$0 Miss −100.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−0% Neutral
Price vs 50-day avg
+9% Bullish
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
53% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+30% holders QoQ · +23 funds added
Insider flow Accumulating
Net +$51.2K over 90 days · 20% sells
Short interest Rising
2.36% of float · ▲ +2.8% MoM · 8.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
61 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $4 · 53% Range high $7
vs 200-day avg 0% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CAMP
Camp4 Therapeutics Corp
this stock
$279.88M -27.2% +436.5% — 2.4%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
61
% held
66.4%
Net QoQ
+1.9M sh
Top holder
Jupiter Topco LLC
Held Float
View
Held by Funds
Fund positions
22
View
Short & Settlement
Short Interest Rising
Shares short
1.5M
Days to cover
8.4d
Change
+40.0K sh
View
Short Volume
Short vol %
11%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
3.0K
Value
$10.1K
As of
Jul 29, 2026
View
Off-Exchange
Off-exchange %
32.9%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$51.2K
Buyers / Sellers
4 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$3.5M
Net income (FY)
$-80.4M
EPS diluted
$-2.65
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
15
View
Exempt Offerings
Offering
Indefinite
Filed
Jun 21, 2022
View
Earnings & Events
Earnings Calls
Last call
Apr 13, 2026
View

Performance

5D 20D 120D MTD YTD
CAMP -0.9% +48.2% -0.7% +29.3% -27.2%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +1.1% +44.9% -11.8% +27.2% -39.1%
Key facts CIK 1736730 CUSIP 13463J101 13F (30d) 63 filings 61 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)